chrisvoncsefalvay/vaers-outcomes huggingface dataset:
This spontaneous case was reported by a consumer and describes the occurrence of DYSPNOEA (having trouble breathing, having trouble breathing when laying down, sleeping in a chair for the last 6 months), INSOMNIA (couldn't sleep well because of that, sleeping in a chair for the last 6 months), MOVEMENT DISORDER (having trouble getting into higher vehicles like SUVs, having trouble going from the kitchen to the bathroom) and PERIPHERAL SWELLING (legs started swelling & are still swollen) in a 69-year-old female patient who received mRNA-1273 (Moderna COVID-19 Vaccine) (batch nos. 039D21A, 045A21A and 040A21A) for COVID-19 vaccination. No Medical History information was reported. On 13-Mar-2021, the patient received first dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) 1 dosage form. On 10-Apr-2021, received second dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. On 27-Oct-2021, received third dose of mRNA-1273 (Moderna COVID-19 Vaccine) (unknown route) dosage was changed to 1 dosage form. In 2021, the patient experienced DYSPNOEA (having trouble breathing, having trouble breathing when laying down, sleeping in a chair for the last 6 months), INSOMNIA (couldn't sleep well because of that, sleeping in a chair for the last 6 months), MOVEMENT DISORDER (having trouble getting into higher vehicles like SUVs, having trouble going from the kitchen to the bathroom) and PERIPHERAL SWELLING (legs started swelling & are still swollen). At the time of the report, DYSPNOEA (having trouble breathing, having trouble breathing when laying down, sleeping in a chair for the last 6 months), INSOMNIA (couldn't sleep well because of that, sleeping in a chair for the last 6 months), MOVEMENT DISORDER (having trouble getting into higher vehicles like SUVs, having trouble going from the kitchen to the bathroom) and PERIPHERAL SWELLING (legs started swelling & are still swollen) was resolving. No concomitant medications were provided by the reporter. It was reported that patient visited a heart doctor and there was no problem with her heart. Patient now went to a lung doctor. Patient was taken Water pills.
dizziness; chills; fever; nausea; diarrhea; This is a spontaneous report from a contactable Consumer (patient). A 31-year-old non pregnant female patient received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration, administered in Arm Right on 14Apr2021 16:45 as dose 2, single for COVID-19 immunization (Age at Vaccination was 31years). The patient medical history included depression from an unknown date and unknown if ongoing. There were no concomitant medications. It was reported that, the patient did not receive any other vaccine in four weeks and any other medications in two weeks prior COVID vaccination. Prior to the vaccination, the patient was not diagnosed with COVID-19. Since the vaccination, the patient had not been tested for COVID-19. Patient had no known allergies. Patient was not a pregnant at the time of vaccination. The patient previously received BNT162B2 (PFIZER-BIONTECH COVID-19 VACCINE, formulation: Solution for injection, Batch/Lot number was not reported), via an unspecified route of administration, administered in Arm Right on 23Mar2021 16:45 as dose 1, single for COVID-19 immunisation (Age at Vaccination was 31years). On 15Apr2021 02:00, the patient experienced dizziness, chills, fever, nausea and diarrhea. Therapeutic measures were taken as a result of events include Tylenol. The outcome of the events was not recovered.  No follow-up attempts are possible. Information on the lot/batch number cannot be obtained. No further information is expected.
developed itchy papule rash back of R hand 12/27/20, on 12/30/20 migrating muscle aches, weakness, fatigue, 1/1/21 itch/pink rash back R elbow and ant. knees; no resp/thrt, no GI ,improved 1/5/21 , now 75% better, tested 31st and 4th negative covid,
Patient presented for her first dose of Pfizer covid-19 vaccination today. She had Covid in the fall.  She has had anaphylactic reaction to antibiotics in the past, was advised she should be evaluated for 30 minutes post vaccination today. She agreed, was seated in the front row of chairs, next to the EMS and RN Observer tables.  This RN checked in frequently with patient throughout her 30 minute observation period, conversing throughout the wait time. She reported feeling anxious about the vaccine and potential for side effects. She had her husband drive her to her appointment today. Her earlobes and forehead were flushed red and dry, but her neck was without redness. She had even, regular respirations and was able to speak clearly without issue.  RN reassured her that we were here, assessing for any changes and were available to help.  After 15 minutes, patient stated her mouth felt dry. RN offered water, patient accepted. She was able to drink and swallow without trouble. Patient's coloring remained the same, but she reported feeling better. She was still able to converse without difficulty.  At about 29 minutes, patient stated she was worried that something may happen after her 30 minutes was up, stated her tongue was starting to feeling thick. RN offered her additional observation with EMS, alerted them to the situation. Patient checked out with RN station and this RN walked her into the hallway for EMS evaluation.  EMS helped patient out of her sweatshirt and mask.  EMS noted lip swelling and increased redness in her face, neck, chest, earlobes.  EMS obtained vitals and administered 50 mg benadryl IM in her right deltoid.  Patient's husband came in from the parking lot. Patient declined solumedrol injection due to her diabetes.  EMS advised patient she needed additional evaluation and she was transported to hospital via ambulance.  Patient's husband followed in his car.  VAERS report filed.
Dx: Myocarditis  first s/s 02/04/2021 Pt with h/o chronic cardiovascular disease, HTN<  Poissble alternative etiology: possible cardiac sarcoid and T cruzi infection as cause for cMRI findings; these were on the differential in the absence of other definitive cause
Tested positive for Covid on 10/03/2022, following severe GI distress. Diarrhea, severe stomach cramps, vomiting, nausea. The episode lasted for 2-3 hours and symptoms subsided. I had intermittent headache and post nasal drip with some coughing. I contacted my clinician and received and took a course of Paxlovid. On 10/11/2022 I tested negative for Covid, but had more severe headache and face pain, and sharply elevated blood pressure. I went to clinic, as diagnosed with sinusitis, prescribed Doxycycline Monohydrate. Returned on 10/20/22 and was prescribed Azelastine nasal spray. I completed 5 days of using Azelastine and today began using Flonase to deal with post nasal drip. Blood pressure is still elevated.
at 1315 pt complain of chest tightness, tongue itchiness and lip[ swelling .
This study case was received from the investigator in a trial on 17 October 2013 with additional information received on 25 October 2013. A female subject with no reported past medical history had received on 30 September 2013 the following vaccinations: ACAM2000 (lot number, route and site not reported), Anthrax (lot number, route and site) and FLUMIST (lot number, route and site) and 10 days later on 10 October 2013, experienced possible myopericarditis. The subject had no cardiac symptoms and was currently being worked up by cardiology. ECG on 10 October 2013 was abnormal with left posterior hemiblock, flat T waves and right ventricular hypertrophy. Troponin I on 10 October 2013 was 6.10 ng/mL. Repeated attempts to contact the subject have failed. No further information regarding work-up or treated was expected to become available. Outcome was reported as not recovered. According to the investigator, the event of possible myopericarditis was possibly related to vaccination and severity of the event was mild. Documents held by sender: none.
neuropathy in her feet and lower legs; This is a spontaneous report from a contactable consumer (patient) received via a sales representative.   A female patient of an unspecified age received bnt162b2 (BNT162B2), dose 2 and dose 1, both via an unspecified route of administration on an unspecified date (Batch/Lot number was not reported) as SINGLE DOSE for COVID-19 immunisation.  The patient's medical history and concomitant medications were not reported.  When the patient received the first dose of vaccine and within approximately 24 to 48 hours, started experiencing neuropathy in her feet and lower legs. Her neuropathy was almost gone and then she got her second vaccine and within 4 hours the neuropathy returned with the same intensity she felt after the first vaccine. The outcome of the event was not recovered.  Information on the lot/batch number has been requested.
The headache in the right eye was most troublesome; Nausea; Diarrhea; Achy; severe exhaustion; This is a spontaneous report received from a contactable consumer. This consumer reported for a 56-year-old male patient received first dose of BNT162B2 (Batch/Lot Number: EN6203), via an unspecified route of administration, administered in Left Arm on 03Mar2021 11:00 am as SINGLE DOSE for covid-19 immunisation. The patient medical history was not reported. The patient's concomitant medications were not reported. Prior to vaccination, was the patient diagnosed with COVID-19: No. Since the vaccination, has the patient been tested for COVID-19: No. Allergies to medications, food, or other products: no. Facility where the most recent COVID-19 vaccine was administered: Doctor's office/urgent care. Patient did not receive any other vaccines within 4 weeks prior to the COVID vaccine. List of any other medications the patient received within 2 weeks of vaccination: Not sure. The patient experienced the headache in the right eye was most troublesome (non-serious), nausea (non-serious), diarrhea (non-serious), achy (non-serious), severe exhaustion (non-serious); all on 03Mar2021 12:00 pm. Treatment was not received for the adverse event.Headache on right side, nausea, diarrhea, achy, severe exhaustion. The headache in the right eye was most troublesome. The outcome of all events was recovering.
J96.00 ACUTE RESPIRATORY FAILURE 1/22/2022 PLEURAL EFFUSION J96.01 ACUTE HYPOXEMIC RESPIRATORY FAILURE 1/23/2022 PLEURAL EFFUSION
The patient received Monovalent Moderna (6 months - 5 years) at 25 mcg/0.25 mL. This is a lower-than-authorized dose administered to the patient. Patient returned 12/13/2022 to receive 6-11y Moderna vaccine.
pt rcvd 2nd dose of Moderna today. She immediately felt dizzy. We had her sit with an ice pack and water bottle and eventually moved her to lie on floor with her feet elevated. Symptoms progressed over the next 30 minutes to include trouble exhaling (not inhaling), hot ears, shaking, pale skin, nausea, lethargy, headache/pounding. Blood pressure was 113/72. Pulse was steady, slightly fast. After 30 minutes she agreed to have us call 911. EMT arrived and assessed patient for a further 20 minutes. She declined transport to ER. She was released by EMT to go home.
Fatigue, chills lasting from 2 hours post- vaccine through the end of the night, vaccine was at 8am, onset of symptoms at 10am lasting until bedtime.
Extreme lethargy, hives, large amount of swelling and redness at injection site that is still persisting, headache, tinnitus, nausea, runny nose, dizziness, itching
Lost taste; Delayed visual approach left eye/right eye; Joint pain in all body; Muscle pain; Pain in IS; A spontaneous report (United States), was received from a consumer (patient), an 81 years-old female patient, unknown race and ethnicity, who was administered Moderna's COVID-19 vaccine (mRNA-1273).  The patient's medical history was not provided. No relevant concomitant medication was reported.  On 28 Jan 2021, prior to the onset of the events, the patient received their first of two planned doses of mRNA-1273 (batch number: 010M20A), intramuscular for the prophylaxis of COVID-19 infection.  On 30 Jan 2021, after the vaccine was administered, the patient experienced pain in injection site, muscle pain and joint pain all body. 0n 02 Feb 2021, the patient noticed vision effect and experienced delayed visual approach in left eye. On 04 Feb 2021, there was no focus in left eye. On 05 Feb 2021, the same problem delayed visual approach started in right eye. The patient still got problems in right eye. The patient also lost taste few days ago on an unknown date. Treatment information was not provided.  Action taken with second dose of mRNA-1273 in response to the events was unknown.  The outcome of the event, delayed visual approach left eye/right eye was not resolved, and that of events lost taste, joint pain in all body, muscle pain, and pain in IS, were considered as unknown at the time of this report.; Reporter's Comments: Very limited information regarding this event/s has been provided at this time.  Further information has been requested.
numbness to L arm, L chest pain, dizziness, L arm bicep twitching and bicep weakness x 2 days (seen at two days)
Day following vax, pt devel aching shoulder & neck, cough & upper respiratory congestion; site of inject was sore from lt elbow to lt ear; There was erythemia @ site of inject; pain in arm took approx 1 wk to subside;
I noticed swelling in his both legs, he became very fussy, sleepy and started having colds sweats all night.
Vomiting; Chills; This spontaneous case, initially received from a pharmacist on 08-Oct-2018, concerns a 29-year-old, adult, female patient.   On 08-Oct-2018, the patient was administered Afluria QIV [influenza vaccine; dose: 0.5 ml, route of administration: intramuscular, anatomical location: deltoid, batch number: YF40408, expiry date: 30-Jun-2019] for active immunization against influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine.   On 08-Oct-2018, within 15-20 minutes of vaccination, the patient experienced a reaction which included vomiting with chills. The patient took two doses of Emetrol (fructose, glucose, phosphoric acid) but continued to vomit. Subsequently, the pharmacist referred the patient to the emergency room (ER). On the same day, the patient went to the emergency room. The next day, on 09-Oct-2018, the patient was resting at home. And the day after that, on 10-Oct-2018, the patient went back to work again and was feeling well.  On 10-Oct-2018, the patient had recovered from the event vomiting and the outcome of the event chills was not reported.  The reporter assessed this case as non-serious.  The reporter assessed this case as non-serious and considered the causality of the events as related to the suspect vaccine.  Follow up received by the pharmacist on 02-Nov-2018: The outcome of the event vomiting was changed from not recovered to recovered. The stop date (10-Oct-2018) of the event vomiting was added in the event tab. It was reported that on the same day, the patient went to the emergency room. The next day, on 09-Oct-2018, the patient was resting at home. And the day after that, on 10-Oct-2018, the patient went back to work again and was feeling well. The narrative was amended accordingly.; Reporter's Comments: A 29-year-old, female patient, experienced chills and vomiting, within 15-20 minutes of vaccination with Afluria Quadrivalent. The company assessed the causality of the events as related considering the plausible temporal relationship between events and suspect vaccine.
arms began flaying uncontrollably; Initial information received on 04-Nov-2019 regarding an unsolicited valid serious case received from a consumer or non-healthcare professional.  This case is linked to cases 2019SA308265 (same reporter)  This case involves a 73 years old female patient whose arms began flaying uncontrollably (skin exfoliation), while she received vaccine INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE [FLUZONE HIGH DOSE].  Medical history, medical treatment(s), vaccination(s) and family history were not provided. At the time of the event, the patient had ongoing Breast cancer female.  On an unknown date in 2016, the patient received a dose of suspect INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE (lot number and expiry date were not reported) via unknown route in unknown administration site.  On an unknown date in 2016 (in the afternoon), the patient's arms began flaying uncontrollably (skin exfoliation), unknown latency following the administration of INFLUENZA USP TRIVAL A-B HIGH DOSE SUBVIRION VACCINE.  Other relevant tests were not reported.  Final diagnosis was flaying uncontrollably.   The patient was taken to urgent care and was placed on fluids; and that the next morning the arms began flaying again; that she was placed on fluids and it resolved self in.  On an unknown date, the patient recovered from the event.
Systemic: Dizziness / Lightheadness-Mild, Systemic: almost fainted-Mild, Systemic: Visual Changes/Disturbances-Mild, Additional Details: Pt came 08/25/2021 to report that he had a reaction to pfizer vaccine 4-5 hrs after receiving it on 08/12/2021. Pt had blurry vision, was light headed and dizzy which lasted for 5 minutes. Pt states that he almost passed out but never lost consciousness. Pt then had a headache that lasted for 30 mins. Pt was better afterwards and was still able to go to the mall.
PATIENT RECEIVED VACCINE FROM OUTSIDE SOURCE ACUTE HYPOXEMIC RESPIRATORY FAILURE CHRONIC HYPOXEMIC RESPIRATORY FAILURE ACUTE ON CHRONIC HYPOXEMIC RESPIRATORY FAILURE RESPIRATORY FAILURE, UNSPECIFIED ACUITY HYPOXIA
Immunizations at 2 and 4 month - 3 hour screaming spell. Immunizations at 6 months - vomiting. All episodes occurred about 6-8 hours after shots.
Had a red splotchy arm three days after shot, Two weeks after first shot had intense painful leg cramping for one night, Two weeks following second shot also had intense leg cramping for one night, two weeks after that started getting stiff joints and body weakness. Then on April 31, woke up with intense shooting pain, pins and needles, and numbness in both hands. This situation has continued ever since. Sought medical appointment in early May, Doctor ordered numerous tests and blood work. A subsequent EMG appointment revealed carpel tunnel in both hands, severe in left hand, moderate in right. No carpel tunnel previously experienced. The stiffness in the knees, ankles and feet has intensified. Find getting out of chairs, toilet seat and bathtub particularly difficult and painful. This reaction seems consistent with auto immune reactions experienced with some vaccines. This progression has taken me from a healthy, mobile 66 year old woman to one who has great difficult moving and has essentially paralyzed and crippled hands. The stiffness in the knees and lower joints has not been addressed. Appointments for seeing a hand surgeon are set for in July and a rheumatologist in September (heavily booked).
Patient suffered a massive ruptured aneurysm on Jan 28, 2021 She has survived but is neurologically devastated She was transported and had an emergency EVD placed, subsequent craniotomy for aneurysm stability, and VP shunt
Next day after booster, pain when swallowed location in chest left side like where stomach meets esophagus; Burping acid reflux; Burping acid reflux. Got worse 5 days out, pain went away 2 days after trying Pepcid ac but the acid reflux is lingering and sitting there lower esophageal; Dose number: 3; This is a spontaneous report from a contactable reporter (consumer or other non-HCP). The reporter is the patient.  A 46-year-old male patient received bnt162b2 (BNT162B2), administered in arm left, administration date 12Jan2022 at 10:00 (Lot number: FL3198) at the age of 46 Years as dose 3 (booster), single for COVID-19 immunisation. Relevant medical history included: "Alcohol allergy" (unspecified if ongoing), notes: Alcohol allergy gives rash and "Egg allergy" (unspecified if ongoing), notes: Eggs give diarrhea. Concomitant medications included multi vitamins chewable. Vaccination history included: Bnt162b2 (DOSE 1, SINGLE; Lot Number: EW0167; Route of administration: unspecified; Anatomical location: Left arm.), administration date: 27Apr2021, when the patient was 45 years old, for COVID-19 immunisation and Bnt162b2 (DOSE 2, SINGLE; Lot Number: EW0185; Route of administration: unspecified; Anatomical site: Left arm; Time of administration: 14:30), administration date: 18May2021, when the patient was 45 years old, for COVID-19 immunisation. The following information was reported: IMMUNISATION (non-serious) with onset 12Jan2022 at 10:00, outcome "unknown", described as "Dose number: 3"; OESOPHAGEAL PAIN (non-serious) with onset 13Jan2022 at 08:00, outcome "recovered" (15Jan2022), described as "Next day after booster, pain when swallowed location in chest left side like where stomach meets esophagus"; ERUCTATION (non-serious) with onset 13Jan2022 at 08:00, outcome "not recovered", described as "Burping acid reflux"; GASTROOESOPHAGEAL REFLUX DISEASE (non-serious) with onset 13Jan2022 at 08:00, outcome "not recovered", described as "Burping acid reflux. Got worse 5 days out, pain went away 2 days after trying Pepcid ac but the acid reflux is lingering and sitting there lower esophageal". Relevant laboratory tests and procedures are available in the appropriate section. Therapeutic measures were taken as a result of oesophageal pain, eructation and gastrooesophageal reflux disease.  Additional information: Prior to vaccination, the patient was not diagnosed with COVID-19. The patient did not receive any other vaccines within four weeks prior to the COVID vaccine. The events did not result in doctor or other healthcare professional office/clinic visit, emergency room or urgent care. Since the vaccination, the patient had been tested for COVID-19.
85 recruits were vaxed w/Td & Yellow Fever @ the same time; pts exp swelling & erythema surrounding vax site to a greater extent than was prev exp;
Immediately after the shot I had the same panic attack but it only lasted 10 minutes this time. The next day I felt alot of muscle soreness and extreme fatigue. Over the course of the next week I began to have severe joint pain in every joint from fingers to toes. Lower back and left hip were especially bad. I have had to walk with a cane since that shot and I have been struggling to hold a pen to write because the pain in my finger and hand joints are so bad.
Information has been received from a pharmacist concerning a patient who in approximately January 2010, "within the last week or within the last 30 days", was vaccinated with PNEUMOVAX 23 (lot # 662270/1135Y) through subcutaneous injection (dose and site not reported). In approximately January 2010, "within the last week or within the last 30 days", the patient experienced injection site reaction soon after. The patient was in the hospital before receiving the vaccine and hospitalization was not due to vaccination. The outcome of injection site reaction was not reported. All telephone attempts to obtain follow up information have been unsuccessful. A standard lot check investigation has been finalized. All in-process quality checks form the lot number in question were satisfactory. The lot met the requirements of the Center for Biologics Evaluation and Research and was released. This is one of the several reports form the same source. Additional information has been requested.